Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone

Bone Marrow Transplantation volume 25, pages 483–487 (2000)Cite this article

Abstract

The role of more intense conditioning for second transplant was evaluated in myeloma patients achieving at least partial remission (PR) after first transplant with melphalan at 200 mg/m2. Forty-three patients received more intensive conditioning for the second transplant. Nineteen patients received cyclophosphamide 120 mg/kg along with melphalan 200 g/m2 (MEL-CY; group 1) while 24 patients received total body irradiation (1125 cGy) in conjunction with melphalan 140 mg/m2 (MEL-TBI; group 2). Forty-three matched control patients were identified from 450 patients receiving melphalan alone for second transplant (MEL200; group 3). Engraftment and toxicities were comparable among the groups with the exception of increased treatment-related mortality of 8% in group 2 compared to none in groups 1 and 3 (P = 0.07). Despite identical CR rates of 74, 71 and 70%, respectively, in groups 1, 2 and 3 (P = 1.0), event-free survival (median: 27, 15 and 61; P < 0.0001) and overall survival (median: 39, 25 and 76 months; P = 0.003) were significantly decreased in patients receiving more intensive conditioning (groups 1 and 2). Lymphocyte recovery, evaluated as a surrogate for immune recovery, was inferior in more intensively treated patients (groups 1 and 2 compared to group 3). Our findings suggest that more intense conditioning appears to have no benefit in patients responding to their first cycle of high-dose therapy and may even be detrimental in this setting. Bone Marrow Transplantation (2000) 25, 483–487.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–96

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  3. Ventura GJ, Barlogie B, Hester JP et al. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma Bone Marrow Transplant 1990 5: 265–268

    CAS  PubMed  Google Scholar 

  4. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma; what have we learned? Blood 1996 88: 838–847

    CAS  PubMed  Google Scholar 

  5. Jagannath S, Vesole DH, Glenn L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support Blood 1992 80: 1666–1672

    CAS  PubMed  Google Scholar 

  6. Cunningham D, Paz-Ares L, Gore M et al. High-dose melphalan for multiple myeloma; long term follow-up data J Clin Oncol 1994 12: 764–768

    Article  CAS  PubMed  Google Scholar 

  7. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma J Clin Oncol 1994 12: 759–763

    Article  CAS  PubMed  Google Scholar 

  8. Anderson KC, Andersen J, Soiffer R et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma Blood 1993 82: 2568–2576

    CAS  PubMed  Google Scholar 

  9. Marit G, Faberes C, Pico JL et al. Autologous peripheral blood progenitor cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma J Clin Oncol 1996 14: 1306–1313

    Article  CAS  PubMed  Google Scholar 

  10. Fermand JP, Chevret S, Ravaud P et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma; results of a phase II trial involving 63 patients Blood 1993 82: 2005–2009

    CAS  PubMed  Google Scholar 

  11. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after remission induction treatment in multiple myeloma. A report of the French registry on autologous transplantation in multiple myeloma Blood 1995 85: 3077–3085

    CAS  PubMed  Google Scholar 

  12. Goldschmidt H, Hegenbart U, Wallmeier M et al. Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy Rec Res Clin Cancer 1998 144: 27–35

    Article  CAS  Google Scholar 

  13. Bjorkstrand B, Svensson H, Ljungman P et al. 2522 autotransplants in multiple myeloma. A registry study from the European group for Blood and Marrow Transplantation (EBMT) Blood 1997 90: 418a

    Google Scholar 

  14. Samlowski WE, Araneo BA, Butler MO et al. Peripheral lymph node helper T-cell recovery after syngeneic bone marrow transplantation in mice prepared with either gamma-irradiation or busulfan Blood 1989 74: 1436–1445

    CAS  PubMed  Google Scholar 

  15. Bianchi A, Montacchini L, Barral P et al. CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4 cells Br J Haematol 1995 90: 625–632

    Article  CAS  PubMed  Google Scholar 

  16. Miguel-Garcia A, Matutes E, Tarin F et al. Circulating Ki 67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy J Clin Pathol 1995 48: 835–839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Munshi NC . Immunoregulatory mechanisms in multiple myeloma Hematol Oncol Clin North Am 1997 11: 51–69

    Article  CAS  PubMed  Google Scholar 

  18. Kay NE, Bone N, Leong T et al. Sequential phenotypic analysis of blood immune cells in myeloma patients treated on ECOG protocol E9486; relationship of immune cell to treatment and outcome Blood 1997 90: 357a

    Google Scholar 

  19. Munshi NC, Jagannath S, Desikan K et al. Significance of recovery of uninvolved immunoglobulin following total therapy in newly diagnosed multiple myeloma Blood 1997 90: 353a

    Google Scholar 

  20. Powles R, Singhal S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation Blood 1998 91: 3481–3486

    CAS  PubMed  Google Scholar 

  21. Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte–macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted CD8- and CD4-specific T-cell responses Blood 1998 91: 2459–2466

    CAS  PubMed  Google Scholar 

  22. Kwak LW, Sternas LA, Jagannath S et al. T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation (PSCT) Blood 1997 90: 579a

    Google Scholar 

  23. Wen YJ, Ling M, Bailey-Wood R, Lim SH . Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma Clin Cancer Res 1998 4: 957–962

    CAS  PubMed  Google Scholar 

  24. Fermand JP, Ravaud P, Chevret S et al. High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multi-center sequential randomized clinical trial Blood 1998 22: 957–963

    Google Scholar 

  25. Attal M, Payen C, Facon T et al. Single versus double transplant in myeloma; a randomized trial of the Inter Groupe Français du Myelome (IFM) Blood 1997 90: 418a

    Google Scholar 

  26. Munshi NC, Desikan KR, Siegel D et al. Preliminary report of clinical efficacy of patient specific vaccination using purified idiotype protein in myeloma Blood 1999 94: 704a

    Google Scholar 

  27. Powles R, Mehta J, Singhal S et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission; 50 cases from a single center Bone Marrow Transplant 1995 16: 241–247

    CAS  PubMed  Google Scholar 

  28. Desikan R, Siegel D, Fassas A et al. DCEP consolidation after tandem autotransplants in high risk multiple myeloma – improved prognosis compared to matched historical controls Blood 1998 92: 660a

    Google Scholar 

Download references

Acknowledgements

This work was supported in part by CA55819 from the National Cancer Institute, Bethesda, MD.

Author information

Authors and Affiliations

  1. Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    KR Desikan, G Tricot, M Dhodapkar, A Fassas, D Siegel, DH Vesole, S Jagannath, S Singhal, J Mehta, D Spoon, E Anaissie, B Barlogie & N Munshi

Authors
  1. KR Desikan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Tricot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Dhodapkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Fassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. DH Vesole
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Jagannath
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Spoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Anaissie
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B Barlogie
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desikan, K., Tricot, G., Dhodapkar, M. et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 25, 483–487 (2000). https://doi.org/10.1038/sj.bmt.1702167

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702167

Keywords

This article is cited by

Search

Advanced search

Quick links